Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (June 2026)
15 slides from Enveric Biosciences's investor presentation, Jun 9, 2026
Slide 1: Q2 2026 Corporate Presentation: Driving Innovation in Mental Health Therapeutics
Nasdaq:ENVB a ENVERICP BlO.& Cel EN Cee NEXT GENERATION MENTAL HEALTH™ Q2 2026 | CORPORATE PRESENTATION Driving Innovation in Mental Health Therapeutics Enveric.com
Slide 2: Disclaimer
Disclaimer No Offer or Solicitation Informadonal ded to sell, or i an offer any vote or approval. It does not constitute a prospectus or fering of a 10 of th 3f 1933, as amended. Fasiional iormetian and Where eo Finale Section 27A of the: 19 ded, of 1234, as amended, Forwarcdooking statements provid
Slide 3: Neuroplastogens Redefining the Next Wave of Psychiatric Treatment
Neuroplastogens Redefining the Next Wave of Psychiatric Treatment Emerging psychedelic and non-hallucinogenic compounds are demonstrating the potential to drive rapid neural plasticity and transform treatment paradigms. Neuroplastogens May Enable Circuit-Level Repair Psychiatry Faces a Major Innovat
Slide 4: Significant Market Opportunities Across Neuropsychiatry
PA xasdaq:ENve Significant Market Opportunities Across Neuropsychiatry ea 3.2t S) $90+ eg Patients Across Total Addressable Target Indications Market PTSD DEPRESSION ANXIETY ADDICTION ocD MIGRAINE Many patients remain inadequately treated in multiple indications ~ r | (4 i ii ie i i Por rnc ene nece
Slide 5: The Current Treatment Paradigm
The Current Treatment Paradigm More than 150 FDA-approved drugs are currently used to treat psychiatric disorders. Weeks Months Years psaeseereseses 2 rere! i el Ceereeeees Yr) Diagnosis Start Limited Early Symptom Dose Adjustments Ongoing Chronic Treatment Improvement Therapy Day1 Day1 Weeks-Months
Slide 6: Neuroplastogens: A New Class of Drugs
Pnasdag:eNve Neuroplastogens: A New Class of Drugs Promotes neuroplasticity in Prefrontal Cortex (PFC) and restores normal function Prefrontal Cortex The Healthy Brain Dynamic coordination between the PFC and the limbic system regulates emotional Neuroplastogens responses! Neuropsychiatric Disorders
Slide 7: Big Pharma Validation of Neuroplastogen Hypothesis
Big Pharma Validation of Neuroplastogen Hypothesis Neuroplasticity: new treatment paradigm for neuropsychiatry Recent Acquisitions A a $1.2 B acquisition* of Bretisilocin abbvie GILGAMESH * On Phase 2A completion * $900 M upfront “a i | $1.225 B acquisition* WS Sh Ee * On Phase 2 completion « Olsu k
Slide 8: Non-hallucinogenic Neuroplastogens: Potential Advantage Over Psychedelics
Non -hallucinogenic Neuroplastogens: Potential Advantage Over Psychedelics Psychedelics Potential Advantage Non-hallucinogenic neuroplastogens eAccess to much larger treatable patient population eChronic or repeat administration eLower regulatory and commercialization friction eStronger compatibilit
Slide 9: EB-003: Dual 5-HT2A Partial Agonist & 5-HT1B Agonist
PE nasdag:ENVB EB-003: Dual 5 -HT2A Partial Agonist &5 -HT1B Agonist Partial 5-HT2A agonism may promote cortical plasticity, while 5-HTIB agonism may stabilize subcortical circuits, reducing anxiety and depression symptoms. Together, they may enable the brain to learn, adapt, and maintain healthier
Slide 10: Target Product Profile
PA nasdaq :ENve Target Product Profile Novel, non-hallucinogenic neuroplastogen for the EB-003 rs treatment of neuropsychiatric disorders Indication(s) MDD, GAD, PTSD, TRD Patient population Adults Mechanism of action 5-HT2A partial agonist and 5-HTIB full agonist Modality Small molecule DMT analog
Slide 11: Data Supporting Target Product Profile
PF vasdag:enve Data Supporting Target Product Profile Mouse: head-twitch response results Mouse: monitored during oral PK study — no observed effects Rat: monitored during oral PK study — no observed effects Dog: monitored during oral PK study — no observed effects DRF showed no observed effects Mou
Slide 12: EB-003 Program Timeline Through Phase 1B
eS EB-003 Program Timeline Through Phase 1B 20, 30, 40, 30, 20, 30, 40 30, 20, 30 PF vasdag:enve CMC for Phase 1 trials CMC for Phase 2 trials Ongoing MoA studigs (non-IND-emabling) IND-Enabling GLP Studies Phase 1A Phase 1B A } w+ — wth te yy PE ———— WL 0 ——— To IND Filing To Phase 1A Top Line read
Slide 13: Enveric Pipeline
Enveric Pipeline Parti EB-003 & EVM301 Series Neuroplastogens Preclinical EVM4O01 Series Neuroplastogens Discovery EB-002 & EVM201 Series Psilocin Prodrugs Preclinical MycoMedica Life Sciences $62 Million Topical Candidates for Radiation Dermatitis Preclinical Aries Science & Technology $61 Million
Slide 14: Management
Management Management Team Joseph Tucker, Ph.D. Chief tive Officer Kevin Coveney, CPA E Financial Office: Peter Facchini, Ph.D. Jillian Hagel, Ph.D. Board of Directors Michael D. Webb Board Chair George Kegler Director, Chair of the Audit Committee Frank Pasqualone Director, Chair of the Compensatio
Slide 15: ENVERIC Wrenearnoain
Nasdaq :ENVB a”. ENVERIC 9 Wrenearnoain BIOSCIENCES Enveric.com DO
Enveric Biosciences — Investor Presentation (June 2026) on 6ix